Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

Jonathan R. Strosberg,Edward M. Wolin,Beth Chasen,M. Kulke,David L. Bushnell,Martyn Caplin,Richard P. Baum,Timothy J. Hobday,A. Hendifar,Kjell Öberg,Philippe Ruszniewski,E. Krenning

Neuroendocrinology（2018）

引用 2|浏览40

暂无评分

摘要

Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

查看译文

关键词

177lu-dotatate,prrt,net,quality of life

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要